CHIEDOZIE OJIMBA: Open Payments
NPI 1689198350 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,267 in 58 payments from 12 companies in 2025. Trend: 2023 $99 · 2024 $641 · 2025 $1,267
Food & beverage: $1,258Education: $9
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $246 |
| ABBVIE INC. | 11 | $239 |
| Alkermes, Inc. | 11 | $235 |
| Indivior Inc. | 4 | $138 |
| Vanda Pharmaceuticals Inc. | 5 | $103 |
| Almatica Pharma LLC | 4 | $103 |
| Corium, LLC | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Axsome Therapeutics, Inc. | 3 | $46 |
| Biogen, Inc. | 1 | $23 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, SUBLOCADE, FANAPT, LOREEV XR, VIVITROL, Azstarys.
Industry payments across MD — which companies pay providers there.
